Jm. Kinowski et al., BAYESIAN-ESTIMATION OF P-AMINOHIPPURATE CLEARANCE BY A LIMITED SAMPLING STRATEGY, Journal of pharmaceutical sciences, 84(3), 1995, pp. 307-311
This study describes a methodology to calculate p- aminohippurate (PAH
) clearance (CL) and volume of distribution (V) with both the populati
on parameters and one or two samples taken during the disposition and
the elimination phase after a single intravenous infusion. The compute
r program P-PHARM was used, and a log-normal distribution and a hetero
scedastic residual error distribution were assumed. Ninety-six patient
s with and without renal insufficiency were available for analysis, an
d a two-compartment model was used for data modeling. Population param
eters were evaluated for 70 patients (mean number of observed concentr
ation per individual, 6) by a three-step approach. In step 1, the comp
uter program was used td estimate the average pharmacokinetic paramete
rs without taking into account the demographic and/or biological facto
rs. In step 2, the relationship between the posterior individual estim
ates and the covariables was investigated with multiple linear stepwis
e algorithm. In step 3, the population parameters were re-estimated co
nsidering the relationship with the covariables. From the regression p
erformed in step 2, the following covariables were included: serum cre
atinine, body surface area, and body weight. The population averages o
f CL and V were 30.7 +/- 2.36 L/h and 10.6 +/- 1.29 L, respectively. T
o evaluate the predictive performance of the population parameters, th
e remaining 26 patients were used. The population parameters combined
with one or two individual PAH plasma concentrations led to a bayesian
estimation of individual CL and V. This estimation was compared with
the classical procedure of parameter estimation (individual fitting fr
om multiple blood samples). For CL and V, bias was not statistically d
ifferent from zero and the precision of these parameters was good. Thi
s procedure enables the estimation of individual pharmacokinetic param
eters for PAH at minimal cost and minimal disturbance for the patient.